The market for follow-on biologics: how will it evolve?

Keywords

Competitor analysis, Incentive, Food and drug administration, Competition (biology), Business

References

• Overview of the Hatch-Waxman Act and its impact on the drug development process.G J Mossinghoff — 1999
• The cost of biopharmaceutical R&D: is biotech different?Joseph A. DiMasi, Henry G. Grabowski — 2007
• The price of innovation: new estimates of drug development costs.Joseph A. DiMasi, Ronald W. Hansen, Henry G. Grabowski — 2003
• Generic Competition in the US Pharmaceutical IndustryAtanu Saha, Henry G. Grabowski, Howard G. Birnbaum — 2006
• Re-naming and re-gaming: Medicare's doomed attempt to reform reimbursement for injectable drugs.J.D. Kleinke — 2004
• Entry and Competition in Generic BiologicsHenry G. Grabowski, David B. Ridley, Kevin A. Schulman — 2007
• Center for the Study of Drug DevelopmentC. Goodman — 1988
• Therapeutic recombinant proteins: trends in US approvals 1982 to 2002.Janice M. Reichert, Cherie Paquette — 2003
• Patents and new product development in the pharmaceutical and biotechnology industriesH. Grabowski — 2003

Cited by

• Putting the value into biosimilar decision making: the judgment value criteria.Mirhelen Mendes de Abreu, Vibeke Strand, Roger A. Levy — 2014
• Market exclusivity for biologics.David E Wheadon — 2010
• Cheaper Clinical Trials: The Real Solution to the Biologic Industry's Gordian KnotAlana Montas — 2011
• The conclusion of a biologic's lifecycle : manufacturing sourcing strategies on the eve of follow-on biologicsDavid M Pasanek — 2008
• The economic pressures for biosimilar drug use in cancer medicinePaul Cornes — 2011
• EL USO DE BIORREACTORES DESECHABLES EN LA INDUSTRIA BIOFARMACÉUTICA Y SUS IMPLICACIONES EN LA INGENIERÍAMauricio A. Trujillo‐Roldán, Norma A. Valdez‐Cruz — 2009
• Pharmaceutical Profits and the Social Value of InnovationDavid Dranove, Craig Garthwaite, Manuel Hermosilla — 2014
• The use of health economics in the early evaluation of regenerative medicine therapiesHelen McAteer — 2011
• Biosimilars: are they ready for primetime in the United States?Bradford R. Hirsch, Gary H. Lyman — 2011
• Market access of biosimilars: not only a cost issueSteven Simoens, Gilbert Verbeken, Isabelle Huys — 2011
• A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance MarketsErnst R. Berndt, Thomas McGuire, Joseph P. Newhouse — 2011
• Market Entry of Biosimilar Low-Molecular-Weight Heparins in Europe: Opportunities and ChallengesIsabelle Huys, Steven Simoens — 2012
• Biosimilars and market access: a question of comparability and costs?Steven Simoens, Gilbert Verbeken, Isabelle Huys — 2012
• Clinical considerations for biosimilar antibodiesHåkan Mellstedt — 2013
• The economic pressures for biosimilar drug use in cancer medicinePaul Cornes — 2012
• Data exclusivity for biologicsHenry G. Grabowski, Genia Long, Richard Mortimer — 2010
• Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticals.Erwin A. Blackstone, Joseph P. Fuhr — 2010
• Biological Generics: A Business CaseSuzanne M. Sensabaugh — 2007
• Immunotherapy in the Initial Treatment of Newly Diagnosed Cancer Patients: Utilization Trend and Cost Projections for Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, and Metastatic Colorectal CancerYa‐Chen Tina Shih, Linda S. Elting, Alexandre L. Pavluck — 2010
• Formulary Selection Criteria for Biosimilars: Considerations for US Health-System PharmacistsNiesha Griffith, Ali McBride, James G. Stevenson — 2014

Related papers

• BIOSIMILARS NEED OF THE FUTURESujata Sawarkar, A. Kore — 2014
• Biologics and biosimilarsPalak K. Patel, Caleb R. King, Steven R. Feldman — 2015
• Practical Considerations for Integrating Biosimilars Into Clinical PracticeMegan May, Kate Deen Taucher, Wendy H. Vogel, MSN, FNP, AOCNP — 2021
• Biosimilars: Current perspectives and future implicationsMonika Misra — 2012
• BIOSIMILAR CURRENT STATUS IN INDIARaju Kamaraj, M Manju — 2016
• Biosimilars in dermatology: identifying myths and knowledge gaps.Palak Patel, Caitlin G. Purvis, Ramiz N Hamid — 2023